IFRX:NASDAQ, InflaRx N.V.
IFRX stock overview
InflaRx N.V. (IFRX:NASDAQ) closed at $1.64 on October 27, 2026,
up 3.81% on the day.
The stock trades 44.6% below its 52-week high of $2.95
and 104.9% above its 52-week low of $0.798.
Over the past year, it lost 5.1%.
InflaRx N.V. is part of the Health Care sector.
Key figures
- Price
- $1.64
- Day change
- +3.81%
- Volume
- 120,803
- Average volume
- 780,850
- Market cap
- 240M+
- 52-week range
- $0.798 – $2.95
- 50-day average
- $1.90
- 200-day average
- $1.62
Price action over the past year
In 252 trading sessions since October 24, 2025, IFRX closed higher on 115 days (46%).
Its best day was April 17, 2026 (+32.50%) and its worst was December 2, 2025 (-14.31%).
The stock moved 10% or more in a single session 14 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
IFRX news
-
Oct 27, 2026:
InflaRx Announces November Investor Events
-
Oct 22, 2026:
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
-
Oct 22, 2026:
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
-
Oct 2, 2026:
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
-
Oct 1, 2026:
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
-
Sep 21, 2026:
InflaRx to Host Virtual Capital Markets Day
-
Aug 20, 2026:
InflaRx Announces Participation in September Investor Conferences
-
Aug 6, 2026:
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
About InflaRx N.V.
InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.
Similar stocks
Find more stocks like IFRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.